	US 11,919,931 B2
	Anti-cancer fusion polypeptide capable of binding both CD137 and glypican-3 (GPC3)
Marlon Hinner, Munich (DE); Rachida Siham Bel Aiba, Munich (DE); Christine Rothe, Dachau (DE); Shane Olwill, Freising (DE); and Corinna Schlosser, Freising (DE)
Assigned to Pieris Pharmaceuticals GMBH, Hallbergmoos (DE)
Filed by Pieris Pharmaceuticals GmbH, Hallbergmoos (DE)
Filed on Feb. 5, 2021, as Appl. No. 17/169,209.
Application 17/169,209 is a division of application No. 15/575,309, granted, now 10,913,778, previously published as PCT/EP2016/061071, filed on May 18, 2016.
Claims priority of application No. 15167927 (EP), filed on May 18, 2015; and application No. 16150508 (EP), filed on Jan. 8, 2016.
Prior Publication US 2021/0403516 A1, Dec. 30, 2021
Int. Cl. C07K 14/47 (2006.01); A61P 35/00 (2006.01); C07K 14/705 (2006.01); C07K 16/28 (2006.01); C07K 16/32 (2006.01)

CPC C07K 14/47 (2013.01) [A61P 35/00 (2018.01); C07K 14/70575 (2013.01); C07K 16/2878 (2013.01); C07K 16/32 (2013.01); C07K 2317/92 (2013.01); C07K 2319/33 (2013.01)]

6 Claims

1. A fusion polypeptide that is capable of binding both CD137 and glypican-3 (GPC3), wherein the fusion polypeptide comprises at least two subunits in any order, wherein the first subunit is specific for CD137 and the second subunit is specific for GPC3 and wherein the second subunit comprises an amino acid sequence of a GPC3-specific lipocalin mutein comprising at least one of the following mutated amino acid residues in comparison with the linear polypeptide sequence of mature human lipocalin 2 (hNGAL) (SEQ ID NO: 2):

Leu 36→Val or Arg; Ala 40→Leu, Val or Gly; Ile 41→Leu, Arg, Met, Gly or Ala; Gln 49→Pro or Leu; Tyr 52→Arg or Trp; Asn 65→Asp; Ser 68→Val, Gly, Asn or Ala; Leu 70→Arg, Ser, Ala or Val; Arg 72→Asp, Trp, Ala, or Gly; Lys 73→Gly, Arg, Asn, Glu or Ser; Cys 76→Val or Ile; Asp 77→His, Met, Val, Leu, Thr or Lys; Trp 79→Lys, Ser or Thr; Arg 81→Gly; Cys 87→Ser; Asn 96→Arg, Asp, Gln or Pro; Tyr 100→Gly, Glu, Pro or Gln; Leu 103→Glu, Gln, Asn, Gly, Ser or Tyr; Ser 105→Ala; Tyr 106→Asn, Ser or Thr; Lys 125→Glu; Ser 127→Arg or Tyr; Tyr 132→Trp or Ile; Lys 134→Ala or Phe; Thr 136→Ile; and Cys 175→Ala.